These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34243115)

  • 1. What Every Clinical Virologist Should Know About The VALID Act On Behalf of the Pan-American Society for Clinical Virology Clinical Practice Com.
    Hata J; Madej R; Babady NE
    J Clin Virol; 2021 Aug; 141():104875. PubMed ID: 34243115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Laboratory-Developed Tests.
    Genzen JR
    Am J Clin Pathol; 2019 Jul; 152(2):122-131. PubMed ID: 31242284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests.
    Graden KC; Bennett SA; Delaney SR; Gill HE; Willrich MAV
    Lab Med; 2021 Jul; 52(4):315-328. PubMed ID: 33283241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Maintenance Cost for Precision Diagnostics Under the Verifying Accurate Leading-Edge In Vitro Clinical Test Development (VALID) Act of 2020.
    Huang R; Lasiter L; Bard A; Quinn B; Young C; Salgado R; Allen J; Lennerz JK
    JCO Oncol Pract; 2021 Nov; 17(11):e1763-e1773. PubMed ID: 33881920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory-developed test regulation and the immunocompromised patient: uncertainty ahead.
    Clark AE; Levy J; Lee FM
    Curr Opin Infect Dis; 2020 Aug; 33(4):304-311. PubMed ID: 32657967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintaining Life-saving Testing for Patients With Infectious Diseases: Infectious Diseases Society of America, American Society for Microbiology, and Pan American Society for Clinical Virology Recommendations on the Regulation of Laboratory-developed Tests.
    Caliendo AM; Couturier MR; Ginocchio CC; Hanson KE; Miller MB; Walker KE; Frank GM;
    Clin Infect Dis; 2016 Jul; 63(2):151-4. PubMed ID: 27118790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory-Developed Tests: A Legislative and Regulatory Review.
    Genzen JR; Mohlman JS; Lynch JL; Squires MW; Weiss RL
    Clin Chem; 2017 Oct; 63(10):1575-1584. PubMed ID: 28687634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests.
    Stone JA; van der Gugten JG
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():82-90. PubMed ID: 36937811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory Developed Tests.
    D'Angelo R; Weiss R; Wolfe D; Chinnam R; Murat A; Gluesing J; Somers T
    Am J Clin Pathol; 2018 Apr; 149(6):484-498. PubMed ID: 29659675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostics Reform and Harmonization of Clinical Laboratory Testing.
    Schreier J; Feeney R; Keeling P
    J Mol Diagn; 2019 Sep; 21(5):737-745. PubMed ID: 31075512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests.
    Lin Y; Thomas SN
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():30-34. PubMed ID: 36865788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities.
    Offit K; Sharkey CM; Green D; Wu X; Trottier M; Hamilton JG; Walsh MF; Dandiker S; Belhadj S; Lipkin SM; Sugrañes TA; Caggana M; Stadler ZK
    J Clin Oncol; 2023 Jan; 41(1):11-21. PubMed ID: 35944238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ideas and Briefing about Regulatory Requirements for Laboratory Developed Tests in the US].
    Han Z; Zhao Y; L Y; Dong J; Deng G
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 Sep; 46(5):534-537. PubMed ID: 36254482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. College of american pathologists proposal for the oversight of laboratory-developed tests.
    Vance GH
    Arch Pathol Lab Med; 2011 Nov; 135(11):1432-5. PubMed ID: 22032569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
    Sidawy MK
    Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center.
    Geno KA; Cervinski MA
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():63-66. PubMed ID: 36846026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malaria Diagnostic Practices in U.S. Laboratories in 2017.
    Prestel C; Tan KR; Abanyie F; Jerris R; Gutman JR
    J Clin Microbiol; 2018 Aug; 56(8):. PubMed ID: 29875196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing.
    Klepser ME; Adams AJ; Srnis P; Mazzucco M; Klepser D
    Res Social Adm Pharm; 2016; 12(4):614-21. PubMed ID: 26508268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2012 Apr; 61(RR-2):1-44. PubMed ID: 22475884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.